Poseida Awarded $19.8M Grant to Continue Developing P-BCMA-101 for Multiple Myeloma – Myeloma Research News
Myeloma Research News |
Poseida Awarded $19.8M Grant to Continue Developing P-BCMA-101 for Multiple Myeloma
Myeloma Research News “Poseida is developing a promising next generation CAR–T cell therapy which includes many of the desirable attributes of emerging CAR–T cell therapies into a single treatment,” Maria Millan, MD, president and chief executive officer of CIRM, said in a … |
